CalciMedica, Inc. (CALC)
| Market Cap | 8.67M -81.7% |
| Revenue (ttm) | n/a |
| Net Income | -21.24M |
| EPS | -6.65 |
| Shares Out | 6.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,134 |
| Open | 1.299 |
| Previous Close | 1.300 |
| Day's Range | 1.270 - 1.340 |
| 52-Week Range | 1.270 - 36.000 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 50.00 (+3,837.01%) |
| Est. Earnings | Nov 11, 2026 |
About CALC
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumati... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CALC stock is "Buy." The 12-month stock price target is $50.0, which is an increase of 3,837.01% from the latest price.
News
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-acti...
Calcimedica Inc trading halted, news pending
19:50 EDT Calcimedica (CALC) Inc trading halted, news pending
CalciMedica to effect 1-for-5 reverse stock split
CalciMedica (CALC) announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-5, effective at 5:00 p.m. ET on August…
CalciMedica Announces One-for-Five Reverse Stock Split
LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activa...
CalciMedica initiated with a Buy at Guggenheim
Guggenheim initiated coverage of CalciMedica (CALC) with a Buy rating and $9 price target The firm is positive on the company’s CM5480, a first-in-class oral Orai1 inhibitor in development for…
CalciMedica Quarterly report: Q2 2026
CalciMedica has published its Q2 2026 quarterly earnings report on August 11, 2026.
CalciMedica announces FDA alignment on Phase 2b Auxora trial design
CalciMedica (CALC) announced that, following a Type C Focused Meeting, the U.S. Food and Drug Administration and the company have aligned on Phase 2b trial endpoints and a patient population…
CalciMedica, FDA alignment de-risks regulatory path, says H.C. Wainwright
FDA alignment on CalciMedica’s (CALC) acute pancreatitis program for Auxora de-risks the regulatory path, validating Phase 2b endpoint selection and patient enrichment strategy while advancing a poten...
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints FDA aligned on a str...
CalciMedica files to sell 56.02M shares of common stock for holders
16:13 EDT CalciMedica (CALC) files to sell 56.02M shares of common stock for holders
CalciMedica Registration statement: Registration filing
CalciMedica filed a registration statement on July 24, 2026, providing details about a securities offering with the SEC.
CalciMedica Proxy statement: Proxy filing
CalciMedica filed a proxy statement on July 23, 2026, providing details for shareholder voting and corporate governance matters.
CalciMedica Proxy statement: Proxy filing
CalciMedica filed a proxy statement on July 13, 2026, providing details for shareholder voting and corporate governance matters.
CalciMedica announces $49M private placement
CalciMedica (CALC) announced it has entered into a definitive securities purchase agreement with leading healthcare investors for a private placement for up to approximately $49M in gross proceeds. Th...
CalciMedica announces FDA review of protocol amendment for Kourage trial
CalciMedica (CALC) announced that the FDA has reviewed a protocol amendment and interim safety data for CalciMedica’s Phase 2 KOURAGE trial in patients with Stage 2 or Stage 3 acute…
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral C...
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue cli...
CalciMedica Quarterly report: Q1 2026
CalciMedica has published its Q1 2026 quarterly earnings report on May 12, 2026.
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480,...
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of pivo...
CalciMedica Registration statement: Registration Filing
CalciMedica filed a registration statement on March 3, 2026, providing details about a securities offering with the SEC.
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNe...
CalciMedica Registration statement: Registration Filing
CalciMedica filed a registration statement on November 13, 2025, providing details about a securities offering with the SEC.
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute pancreati...
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with ex...